Case Type: Mergers & Acquisitions

Chord Energy Corp. (Nasdaq: CHRD), relating to its proposed merger with Enerplus Corp. Under the terms of the agreement, Enerplus shareholders are expected to receive 0.10125 shares of Chord plus $1.84 in cash per share they own.

Atreca, Inc. (Nasdaq: BCEL), relating to its proposed sale to Immunome, Inc. Under the terms of the agreement, BCEL is expected to be paid up to $12.5 million dollars.

Encore Wire Corporation (Nasdaq: WIRE), relating to its proposed sale to Prysmian. Under the terms of the agreement, WIRE shareholders are expected to receive $290.00 in cash per share they own.

Alpine Immune Sciences, Inc. (Nasdaq: ALPN), relating to its proposed sale to Vertex Pharmaceuticals Inc.. Under the terms of the agreement, ALPN shareholders are expected to receive $65.00 in cash per share they own.

Inrad Optics, Inc. (Other OTC: INRD), relating to its proposed sale to Luxium Solutions. Under the terms of the agreement, INRD shareholders are expected to receive $1.10 in cash per share they own.

Apartment Income REIT Corp. (NYSE: AIRC), relating to its proposed sale to Blackstone. Under the terms of the agreement, AIRC shareholders are expected to receive $39.12 in cash per share they own.

Model N, Inc. (NYSE: MODN), relating to its proposed sale to Vista Equity Partners. Under the terms of the agreement, MODN shareholders are expected to receive $30.00 in cash per share they own.

Shockwave Medical, Inc. (Nasdaq: SWAV), relating to its proposed sale to Johnson & Johnson. Under the terms of the agreement, SWAV shareholders are expected to receive $335.00 in cash per share they own.

Kintara Therapeutics, Inc. (Nasdaq: KTRA), relating to its proposed merger with TuHURA Biosciences, Inc.

ARCA Biopharma, Inc. (Nasdaq: ABIO), relating to its proposed sale to Oruka Therapeutics. Under the terms of the agreement, ABIO shareholders are expected to own approximately 2.38% of the combined company.